a) Dose-dependent transfection studies of NSMD platform and three control studies (i.e., Lipo-2000, RGD-jet-PEI, and pEGFP⊂SNPs in absence of Ad-SiNWS) were performed in parallel. b) Time-dependent transfection studies in the presence of pEGFP⊂SNPs; maximum transfection was achieved 12 h post administration of pEGFP⊂SNPs. c) A diversity of mammalian cells, including adherent cells (i.e., HeLa, NIH3T3, MCF7, and HEK293), suspension cells (i.e., BC-1, Ramos, and Jurkat), and primary cells (i.e., BJ, HDF, J1, MEF, and hNSC) were introduced onto the NSMD platform in the presence of pEGFP⊂SNPs. NSMD exhibited 70–98% transfection efficiency among different mammalian cells, significantly higher than those observed for a Lipo-2000-based delivery system at similar experimental conditions. d) A single batch of U87 cells on Ad-SiNWS were sequentially treated by three different SNP vectors with encapsulated DNA plasmids (specifically encoding EGFP, mCherry, and E2-Crimson) at 12, 24, and 36 h post cell settlement. e) Micrographs show that each individual gene can be effectively delivered into and then expressed by the cells with superb transfection performance.